INTRODUCTION
The primary structure of the biosynthetic precursor of human calcitonin (preprocalcitonin) may be deduced from the nucleotide sequence of cDNA clones isolated from medullary thyroid carcinoma tissue (Craig et al., 1982; Le Moullec et al., 1984) and from a bronchial carcinoma cell line (Riley et al., 1986) . Human preprocalcitonin is a protein comprising 141 amino acid residues in which the calcitonin sequence is flanked at its C-terminus by a 21-residue peptide termed katacalcin or PDN-21. The gene directing the synthesis of human calcitonin (CALC-I) comprises six exons (Edbrooke et al., 1985; Steenbergh et al., 1986) and gives rise to two mRNAs by an alternative RNA-processing mechanism (Steenbergh et al., 1984; Jonas et al., 1985) . Preprocalcitonin mRNA contains the products of transcription of exons 1-4, and preprocalcitonin-gene-related peptide (preproCGRP) mRNA contains the products of transcription of exons 1-3, 5 and 6. Both preprocalcitonin mRNA and prepro-CGRP mRNA are expressed in a variety of healthy tissues including thyroid (Tschopp et al., 1984) and in tumours of the thyroid (Morris et al., 1984) and lung (Edbrooke et al., 1985) . The human genome contains a second calcitonin/CGRP gene (CALC-II) that is structurally similar to the CALC-I) gene (Steenbergh et al., 1985) . The CALC-II RNA transcripts do not appear to be differentially processed, as only preproCGRP-II mRNA and not preprocalcitonin-II mRNA is detected in tissues that express the CALC-I gene (Alevizaki et al., 1986; Steenbergh et al., 1986) . Previous studies have shown that the calcitonin-like immunoreactivity in extracts of human tumours of the thyroid (Desplan et al., 1980; Dermody et al., 1981) , lung (Lumsden et al., 1980; Zajac et al., 1985) and pancreas (Galmiche et al., 1980; Tobler et al., 1983 ) is heterogeneous. High-molecular- 
EXPERIMENTAL Preparation of tumour material
Details of the patient and a description of the histopathology of the tumour have been provided in a previous paper (Conlon et al., 1988 (v/v) trifluoracetic acid. Cysteine residues in procalcitonin-(60-116)-peptide were alkylated by using 4-vinylpyridine by the method of Andrews & Dixon (1981) . The pyridylethylated peptide was isolated by h.p.l.c. under the same conditions of chromatography used for the purification of the unmodified peptide.
Digestion with CNBr
Procalcitonin-(1-57)-peptide (approx. 10 nmol) was incubated with a small crystal of CNBr for 16 h at room temperature in 70 % (v/v) formic acid (100 ,ul). The reaction mixture was freeze-dried. Peptide fragments were isolated by chromatography on a Vydac 218TP54 column equilibrated with 0.1 % (v/v) trifluoroacetic acid at 30°C and at a flow rate of 1.5 ml/min. The concentration of acetonitrile in the eluting solvent was raised to 490 (v/v) over 60 min.
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Structural analysis Amino acid compositions were determined by using a Durrum automatic analyser as described previously (Conlon et al., 1987) . Cysteine and tryptophan residues were not measured. Amino acid sequence analysis was carried out by automated Edman degradation in an Applied Biosystems model 470 A gas-phase sequencer . The detection limit for amino acid phenylthiohydantoin derivatives was 0.5 pmol.
Radioimmunoassay methods
Calcitonin-like immunoreactivity was measured by the use of an antiserum raised against human calcitonin supplied by Calbiochem-Behring (La Jolla, CA, U.S.A.). The radioimmunoassay was carried out according to the supplier's instructions, and human calcitonin from Peninsula Laboratories (Europe) Ltd. (St. Helens, Lancs., U.K.) was used as standard. The detection limit for the assay was 23 fmol/ml. Calcitonin-gene-related peptide (CGRP) was measured by the use of an antiserum supplied by Peninsula Laboratories (Europe) Ltd. that shows equal reactivity with human CGRP-I and CGRP-II. Human CGRP-I from Peninsula Laboratories (Europe) Ltd. was used as standard. The detection limit for the assay was 33 fmol/ml.
RESULTS

Concentrations of calcitonin and CGRP in the tumour extract
The concentration of calcitonin-like immunoreactivity in the tumour extract was 32.6 nmol/g wet wt. The antiserum used in the radioimmunoassay showed only very low reactivity with procalcitonin-(60-116)-peptide [procalcitonin-(60-116) -peptide] is shown in Fig. 2 , and the purification of peak 4 material [procalcitonin-(1-57)-peptide] is shown in Fig. 3 . The approximate final yields of purified peptides were: procalcitonin- , 1984) . Digestion of peak 2 material with CNBr generated two major peptide fragments whose amino acid compositions (Table 1) indicated identity with the expected procalcitonin-(1-36)-peptide and procalcitonin-(37-57)-peptide. The homoserine lactone residue at the C-terminus ofprocalcitonin-(1-36)-peptide was not quantified. The primary structures of the procalcitonin-derived peptides were confirmed by automated Edman degradation ( Table 2 ). The complete amino acid sequences of procalcitonin-(1-36)-peptide, procalcitonin-(37-57)-peptide and procalcitonin-(60-116)-peptide were obtained with the exception that no amino acid phenylthiohydantoin derivative corresponding to homoserine lactone was observed at cycle 36 of the Edman degradation of procalcitonin-(1-36)-peptide. The primary structures of the peptides are identical with the structures predicted from the nucleotide sequences of cloned cDNAs from human tumours of the thyroid (Le Moullec et al., 1984) and lung (Riley et al., 1986 
DISCUSSION
The high level of expression of the calcitonin (CALC-I) gene in a human medullary thyroid carcinoma has enabled the isolation of peptides that together comprise the full sequence of procalcitonin. The very high concentration of calcitonin-like immunoreactivity in the tumour extract estimated by radioimmunoassay was consistent with the observation that nearly all tumour cells were immunostained by the use of an antiserum to calcitonin (Conlon et al., 1988) . A previous study with the same tissue extract has led to the isolation of the immunoregulatory peptide, thymosin f4 (Conlon et al., 1988) . A comparison of the predicted amino acid sequences of preprocalcitonin and preproCGRP indicates that the precursors share a common N-terminal sequence of 75 amino acid residues (Le Moullec et al., 1984; Edbrooke et al., 1985) . The N-terminal flanking sequence to calcitonin in preprocalcitonin terminates in Ser76-Leu78-Asp79-Ser80-Pro81-Arg82-Ser83, whereas the corresponding sequence in proCGRP is Arg76-Ile77-Ile78-Ala79-Gln80. Structural characterization of procalcitonin-(1-57)-peptide confirms that this component is derived from preprocalcitonin and establishes the site of cleavage of the signal peptide as the Ala25-Ala26 bond. This conclusion is in agreement with the results of partial N-terminal microsequencing of radiolabelled procalcitonin synthesized by a human medullary thyroid carcinoma cell line (Gkonos et al., 1986) . The site of cleavage of the signal peptide in rat preprocalcitonin is the corresponding Ala25-Val26 bond (Birnbaum et al., 1984) .
The heterogeneity of the calcitonin-like immunoreactivity in tissue extracts and plasma arises from dimerization and oxidation of the calcitonin monomer and from the presence of incompletely processed biosynthetic intermediates of higher molecular mass (Dermody et al., 1981; Tobler et al., 1983) . The presence of glycosylated forms of human procalcitonin in tumour extracts has been claimed (Baylin et al., 1981) , but no evidence for such components was obtained by other workers (Goltzman & Tischler, 1978; Cate et al., 1986) . The calcitonin sequence in procalcitonin is separated from the katacalcin sequence by the tetrapeptide Gly-Lys-Lys-Arg. After proteolytic cleavage at the site of the basic residues, the glycine residue functions as donor to the ac-amidated Cterminal proline residue of calcitonin. In healthy man, calcitonin and katacalcin circulate in approximately equimolar concentrations, suggesting that processing of procalcitonin at this site is virtually complete (Hillyard et al., 1983) . The isolation of procalcitonin-(60-116)-peptide in relatively high yield has identified an aberrant pathway of post-translational processing in the tumour cells in which the site is not utilized by the cleavage enzyme(s). The proposed pathway is illustrated schematically in Fig. 4 . A biologically active peptide with the same elution properties on reverse-phase h.p.l.c. as procalcitonin-(60-116)-peptide was identified in an extract of a benign human pancreatic tumour, but structural characterization was not attempted (Tobler et al., 1983) .
In addition to post-translational processing at the site of pairs or groups of basic amino acid residues (Steiner et al., 1974) , proteolytic cleavage of prohormones at the site of single arginine residues has been described for several systems (Schwartz, 1986; Benoit et al., 1987) . Similarly, cleavage at the site of a Leu-Leu bond has been observed in prosomatostatin (Schmidt et al., 1985) and is involved in the formation of angiotensin I. The Nterminal flanking sequence of human procalcitonin (residues 1-57) contains four potential single arginine cleavage sites and two potential Leu-Leu cleavage sites. The amino acid compositions of the peptides in all the major peaks shown in Fig. 1 have been determined, and no evidence for the presence of peptides arising from cleavage at the Arg4, Arg23, Arg47 or Arg56 residues or from cleavage of the Leu24-Leu25 or Leu25-Leu26 bonds was obtained. 
